DAX24.340 +0,2%Est505.753 +0,1%MSCI World4.343 -0,1%Top 10 Crypto11,38 -1,7%Nas23.562 +0,6%Bitcoin73.552 -0,7%Euro1,1797 ±0,0%Öl62,41 -0,1%Gold4.489 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F DroneShield A2DMAA NVIDIA 918422 Rheinmetall 703000 Deutsche Telekom 555750 Lufthansa 823212 Bayer BAY001 Allianz 840400 Tesla A1CX3T D-Wave Quantum A3DSV9 Infineon 623100 Siemens Energy ENER6Y Amazon 906866 TUI TUAG50 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt vor Weihnachten etwas höher -- Alphabet kauft Intersect -- Novo Nordisk, D-Wave, Lufthansa, Palantir, TUI, Microsoft, Bitcoin, Gold im Fokus
Top News
So bewegen sich die Preise von Gold, Öl, Erdgas und Silber am Mittwochvormittag So bewegen sich die Preise von Gold, Öl, Erdgas und Silber am Mittwochvormittag
NVIDIA-Aktie profitiert: Ray Dalio sieht im Nahen Osten einen der mächtigsten KI-Hubs entstehen NVIDIA-Aktie profitiert: Ray Dalio sieht im Nahen Osten einen der mächtigsten KI-Hubs entstehen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
194,00 EUR +0,40 EUR +0,21 %
BMN
228,74 USD +0,83 USD +0,36 %
BTT
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.341,68 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
PR NewswireAbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireNew Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
PR NewswireAbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
PR NewswireAbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
PR NewswireAbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
PR NewswireAbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
PR NewswireAbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
PR NewswireFifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever
PR NewswireResults Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
PR NewswireRoundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS)
PR NewswireBOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before
PR NewswireAllergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
PR NewswireAbbVie's RINVOQ® (upadacitinib) Receives Health Canada Approval as the First and Only Oral Therapy for the Treatment of Adults with Moderately to Severely Active Crohn's Disease
PR NewswireAbbVie's EPKINLY™ (epcoritamab injection/epcoritamab for injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patie...
PR NewswireAbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
PR NewswireAbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
PR NewswireAbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
PR NewswireAbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
PR NewswireAbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
PR NewswireNature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
PR NewswireAbbVie to Host Third-Quarter 2023 Earnings Conference Call
PR NewswireAbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
PR NewswireAbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
PR NewswireAbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"
PR NewswireAbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
MyDividendsAbbVie wird eine stabile Dividende auszahlen
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie to Present at the Morgan Stanley Healthcare Conference
PR NewswireJournal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)
PR NewswireAbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis
PR NewswireAbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
PR NewswireAllergan Aesthetics Announces First Ever JUVÉDERM® Day
PR NewswireAbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
PR NewswireSKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
PR NewswireHealth Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PR NewswireAbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
PR NewswireAbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
PR NewswireAbbVie to Host Second-Quarter 2023 Earnings Conference Call
PR NewswireAbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.